Statistics

Total Visits

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease14

Select a period of time:

Number of views in the range

Views
A phase II, multicenter, four-cohort study of oral cMET inhibitor capmatinib (INC280) in patients with EGFR wild-type, advanced NSCLC who have received one or two prior lines of systemic therapy for advanced/metastatic disease8

Views

Views
May 20243
June 20241
July 20242
August 20241
September 20241
October 20240
November 20240
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States8
 

Top cities views

Views
Chicago5